Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Pipeline
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.

Continue
  • News & Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
thumbnail

Replay: Third Quarter 2021 Financial Results Conference Call

thumbnail

Replay: Second Quarter 2021 Financial Results Conference Call

thumbnail

Replay: First Quarter 2021 Financial Results Conference Call

thumbnail

Full-Year 2020 Earnings Call

thumbnail

Replay: Second Quarter 2020 Financial Results Conference Call

thumbnail

Replay: First Quarter 2020 Financial Results Conference Call

thumbnail

Replay: Year End 2019 Financial Results Conference Call

thumbnail

Replay: Solebury Trout Virtual Global Healthcare Conference Series

thumbnail

Replay: Pieris Pharmaceuticals R&D Day

thumbnail

Replay: Third Quarter 2019 Financial Results Conference Call

RSS
  • 1
  • 2
  • 3
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences